OncoHost

10/15/2025

We’re excited to share that OncoHost will present new research at on using plasma proteomics to guide treatment selection in metastatic melanoma.

Another step forward in advancing truly personalized cancer care. 💡

Read the full news release here: https://prn.to/4hfGVpR

/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that its latest...

10/13/2025

Did you know? Lung cancer is more treatable when caught early. During Healthy Lung Month, we encourage everyone at risk to talk to their doctor about low-dose CT scans and biomarker testing. Early answers save lives.

10/09/2025

Are your lungs healthy? In honor of Healthy Lung Month, it’s the perfect time to check in on your respiratory health.

Breathing should feel effortless, but rising air pollution, past infections, lifestyle choices, and smoking can all take a toll. Blood work (ABG, CBC, CMP), TB screening, and genetic checks can help assess your lung function and catch problems early.

Take a moment this month to learn how to keep your lungs strong and healthy. Your lungs work for you every second—return the favor!

Read more:

On World Lung Day 2025, understand how to keep your lungs healthy and prevent respiratory problems. For expert insights, we got in touch with Dr. Sudhir Kr. Gupta on identifying early signs of lung issues, maintaining lung health through lifestyle choices, and taking precautions against pollution, i...

10/06/2025

October is Healthy Lung Month - a reminder to protect the lungs that protect you. From avoiding smoking to improving air quality and keeping up with screenings, small steps today can mean healthier lungs tomorrow.

10/03/2025

Only 16% of people eligible for lung cancer screening in the U.S. are getting lifesaving scans, and too many patients begin treatment without first receiving comprehensive biomarker testing.

We applaud the American Lung Association’s new campaign to raise awareness about both screening and biomarker testing, shaped by the voices of patients and caregivers.

At OncoHost, we believe every lung cancer patient deserves access to the right tests at the right time. Screening can catch cancer early, and biomarker testing ensures patients receive the most effective, personalized treatment options.

Learn more: Lung.org/lungcancer

From the basics through treatment and beyond, get the information you need about lung cancer.

10/01/2025

Today is National Previvor Day 💙

We honor those taking proactive steps to reduce their cancer risk or do genetic testing, and the companies who are advancing technologies for early detection.

09/26/2025

PROphetNSCLC® provides insights to answer the question: Which first-line therapy is more likely to improve overall survival of the patient?

✔️ One blood draw
✔️ Results 8 days from sample receipt at our CLIA-certified and CAP-accredited lab
✔️ Guides first-line treatment decisions

Transform complex data into actionable guidance to deliver care that's truly individualized: oncohost.com/order-a-test

09/22/2025

Exciting news for early cancer detection! Exact Sciences has just launched Cancerguard, a multi-cancer early detection blood test which can detect signals from more than 50 types. Many of these cancers do not even currently have an existing screening method.

At OncoHost, we’re excited to see more innovation in blood-based testing. Like , we also use liquid biopsy technology, but for guiding first-line treatment planning.

saves lives, and blood tests make it accessible. We're looking forward to seeing the impact of more test like this coming to the market.

Read more about their test here:

Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection ...

09/18/2025

Our recognition as Top Precision Oncology Solution for 2025 by Life Sciences Review continues to make waves!

This latest feature spotlights how our PROphet® platform, powered by AI and proteomics, is redefining how oncologists predict patient response to immunotherapy and personalize treatment strategies.

We’re proud to see growing awareness of the importance of shifting focus from the tumor alone to the host response, and the role PROphet® plays in guiding treatment decisions.

Read the full article here: https://bit.ly/4nDjRmX

PROphet® uses a blood test to analyze thousands of plasma proteins and predict how patients are likely to respond to immunotherapy.

09/16/2025

🌍 Air pollution and lung cancer: progress uneven across the globe

A new study in the International Journal of Public Health reveals that while PM2.5-related cancer deaths are declining in the U.S., Japan, and South Korea—thanks to stronger air quality policies—China continues to carry a disproportionately high burden.

Why this matters: Beyond cutting emissions, tackling cancer requires tools that integrate environmental exposures, biology, and predictive analytics to guide prevention and treatment strategies.

Read more here: https://bit.ly/4po4hgr

The study highlights the need for stronger air quality measures as global lung cancer deaths linked to pollution are projected to rise, especially in China.

09/15/2025

🚀 Precision oncology is no longer just the future - it’s here today.
At OncoHost, we’re combining proteomics + AI to give oncologists the actionable insights they need, right when it matters most.

Because every treatment decision reshapes a future.

👉 Learn how PROphet® is amplifying oncologists’ expertise and changing the conversation in cancer care.
https://bit.ly/4cgNODS

Explore OncoHost's PROphet Technology, a cutting-edge precision oncology platform driving advancements in biomarkers for cancer treatment decisions.

09/11/2025

Our latest SCLC research unveiled at

Proud to share our poster presented at the World Conference on Lung Cancer (WCLC) 2025 in Barcelona:
“Distinct Clinical and Biological Features of Five SCLC Subtypes Identified by Plasma Proteomic Analysis.”

This study highlights how plasma proteomics can uncover distinct subtypes of small cell lung cancer (SCLC), offering a minimally invasive path to improved patient stratification and more precise treatment strategies.